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therapy. Biochemical failure (after receiving both EBRT 
and/or BQT) was based on Phoenix definition. Acute and late 
genitourinary and gastrointestinal toxicities were 
documented based on Common Terminology Criteria for 
Adverse Events (v4.0). Median follow-up after HDRB was 36 
months (7-109 months). 
Results: At the time of the study the 3-year biochemical 
relapse-free rate was 58% (74-42, 95% CI). Local relapse was 
13% (23-3, 95% CI). 3-year systemic relapse rate was 7’4% 
(8’12-7’04, 95% CI) and the 3-year overall survival rate was 
91% (101-81, 95% CI). Late genitourinary Grade 3 and 4 were 
8’3% and 3’3%, respectively. Nine patients required urinary 
catheter, 5 patients required transurethral resection and 2 
pts required suprapubic cistostomy. No Grade 3 or 4 rectal 
toxicity were observed in our study. 
Conclusions: Salvage prostate HDRB is an effective modality 
for locally recurrent cancer after EBRT with an acceptable 
late genitourinary toxicity of 8’3%. 
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Purpose/Objective: The dosimetry of 106Ru plaques typically 
relies on one-dimensional dose measurements on the central 
axis of the brachytherapy source. However, to better 
characterize the dosimetric properties and for comprehensive 
quality assurance of different applicator models 
multidimensional measurements are necessary, which in turn 
can be used for treatment planning. In this study 
radiochromic film measurements were performed in multiple 
planes and benchmarked with Monte Carlo (MC) simulations, 
micro-diamond and diode measurements in terms of absolute 
dose rates and relative dose distributions. 
Materials and Methods: Using EBT3 films 2D dose 
distributions of three different applicator models (CCA, CCB 
and COB) were measured parallel to the central axis as well 
as on normal planes in a purpose-built and in-house 
developed polystyrene phantom. Source non-uniformity was 
evaluated in-air using films in a simple setup. All applicators 
were modeled using the MCNP6 MC code. Reference dose 
rates and dose distributions of MC and films were validated 
against BEBIG values and micro-diamond and diode 
measurements performed in a water-scanning phantom. The 
benchmarked dose distributions were superimposed on 
representative tumor geometries of a broad range of clinical 
target sizes. The respective dosimetric margins were 
determined for a given combination of target and applicator 
size in order to assess the applicator types in terms of their 
limits concerning tumor coverage and tumor volume.  
Results: The agreement of absolute dose rates at a reference 
depth of 2 mm on the central axis of the applicator was 
better than 5 % comparing film measurements with respect to 
the manufacturer's data. The source non-uniformity 
evaluation yielded values < 10 %. The MC absolute dose rates 
showed larger deviations with up to 10 % deviations from film 
results. These high differences were close to the plaque's 
surface but quickly vanished for depths > 2-3 mm, depending 
on the applicator model. For the depth-dose profiles the 
measurements yielded a reproducibility (1 SD) < 4 % for all 
investigated applicator types and all detectors. A comparison 
of measured and calculated data using local γ-index criteria 
of 1 mm/5 % showed pass rates > 94 %. Tumor coverage was 
evaluated regarding the dose prescribed to the tumor apex. 
It was found that for a majority of cases the tumor volume is 
either not sufficiently covered by the 100 % prescription 
isodose or does not provide a margin to allow for dosimetric 
uncertainties if the difference between applicator diameter 
and basal diameter ≤ 4 mm. 
Conclusions: Multidimensional film dosimetry for 106Ru eye 
applications was successfully established and validated 
against MC calculations as well as other experimental 
methods. Both absolute and relative dose measurements 
were well within the tolerances given by the manufacturer. 
The multidimensional dosimetric information can be utilized 
in treatment planning.  
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Purpose/Objective: Inverse planning software for HDR 
brachytherapy currently used in hospitals employ dose-based 
penalty functions. The resulting treatment plans may require 
manual a posteriori adjustments to meet clinical criteria. As 
treatment plans are changed intraoperatively after catheter 
insertion, computation speed is a relevant criterion. 
Therefore, new algorithms need to be developed that 
directly and rapidly optimize clinically relevant dose-volume 
histogram (DVH)-criteria. These algorithms rely on expensive 
general purpose solvers. In this work, we propose a local 
search algorithm, DVH-Optimization by Pure Simulated 
Annealing (DOPSA), which is independent of cost-intensive 
general purpose solvers, directly optimizes for clinically 
relevant criteria, and provides high-quality treatment plans 
within seconds. 
Materials and Methods: We have devised a simulated 
annealing-based local search algorithm that maximizes the 
prostate volume receiving the prescribed dose,V100% , while 
strictly complying to imposed DVH-constraints, D10% and Dmax, 
on rectum and urethra. The algorithm's architecture allows 
extensions to more constraints. The computationally most 
constraining step is addressed by efficient large-scale sparse 
matrix multiplication. Constraint satisfaction is 
parsimoniously evaluated and neighborhood searches 
dynamically adjust to local search space characteristics. The 
algorithm is compared to two existing DVH-based inverse 
planning solutions, IPIP by Siauw et al.(2011) and MILP by 
Gorissen et al. (2013), using data of three patients. 
Results: Any solution by the algorithm provides a treatment 
plan which conforms to the imposed DVH-criteria. Based on 
the available data of three patients, the proposed algorithm 
displays advantages over both alternative optimizers: DOPSA 
consistently outperforms IPIP in plan quality at negligible 
differences in speed. MILP takes considerably longer to 
provide plans of comparable quality but, given sufficient 
